Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Eyevensys Appoints Dr Ivan Cohen-Tanugi as CEO

Published: Tuesday, March 26, 2013
Last Updated: Tuesday, March 26, 2013
Bookmark and Share
Dr Ivan Cohen-Tanugi, with over 20 years’ experience in the international pharmaceutical industry, will prepare Eyevensys to launch clinical trials for the company’s non-viral gene therapy processes in two ophthalmic indications.

Eyevensys has announced the appointment of Dr Ivan Cohen-Tanugi as CEO.

Having worked for Sanofi, Amgen International, Roche Pharma and Teva Pharmaceuticals, Dr Cohen-Tanugi first plans to conclude Eyevensys’ preclinical tests over the next 12 months. The first human tests are planned within 18 months.

The Eyevensys process is an electrotransfer of plasmids in the ciliary muscle of the eye.

The Eyevensys team is one of a small group that has reached an advanced stage of development of the process using a non-viral approach.

This treatment is less invasive than current treatments. It allows for injections to be administered from either once a fortnight or monthly to once every six months.

This reduces the dose of drugs and proteins, consequently reducing side effects.

The first preclinical results from animal subjects show therapeutic protein expressions for up to nine months. These results have been the focus of articles published in reputed scientific journals.

“I am delighted to have been given the responsibility of leading Eyevensys through to the next stages of its development,” said Dr Ivan Cohen-Tanugi , CEO at Eyevensys.

Dr Cohen-Tanugi continued, “Eyevensys is backed by stable and trusted investors who are very involved in the business’ development. A new financing round is planned for this year. We hope to sign up new stakeholders, notably on an international level, to diversify our support and proceed up to Phase II.”

“Ivan Cohen-Tanugi’s extensive experience in the pharmaceutical and biotechnological fields will contribute to Eyevensys’ ability to move at a faster pace and proceed to the clinical phase in the best possible circumstances,” said professor Francine Behar-Cohen, Eyevensys’s founder and scientific advisor. “Our key goal is to discover proofs of concept for the electrotransfer process in humans.”

The company targets two main indications, where medical needs are currently urgent and unmet:
• Uveitis, an orphan disease, is an inflammation of the uvea (iris, ciliary body and/or choroid). It causes 10 per cent of cases of blindness in Western countries.

• Age-related Macular Degeneration (AMD) is a disease caused by a gradual degeneration of the macula, the central part of the retina, which can appear from age 50 and more frequently from age 65. It causes a significant weakening of visual capabilities, but does not destroy them.

The exact causes of this condition are unknown. No cure has yet been found. Existing treatments can only slow its progression. As much as 12 per cent of the population between ages 65 and 75 have AMD. It is the leading cause of non-correctable blindness in the western world. Due to population aging, its prevalence may increase by nearly 50 per cent by 2020. Worldwide, an estimated 25 million people are affected.

Dr Cohen-Tanugi, aged 51, has more than 20 years of experience in the international pharmaceutical and biotechnological industry. Before joining Eyevensys, he was vice president and general manager of the Biologics and Specialty unit at Teva Pharmaceuticals in the USA.

He has considerable experience in biologics and the pharmaceutical industry on an international level, notably in the fields of sales and marketing, global product launches, R&D team leadership and financing.

He worked in Switzerland for many years for Roche Pharma, then for Amgen International and finally for Teva Pharmaceuticals. Cohen-Tanugi started his career at Sanofi, where he held various positions in France and the USA. He is trained as a doctor and also holds an MBA from the HEC Business School.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More Than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Eyevensys Announces an Equity Investment by Boehringer Ingelheim Venture Fund
Dr Michel Pairet, Boehringer Ingelheim's head of non-clinical research and development, joins Eyevensys’ board of directors.
Thursday, April 11, 2013
Scientific News
Criminal Justice Alcohol Program Linked to Decreased Mortality
Institute has announced that in the criminal justice alcohol program deaths dropped by 4.2 percent over six years.
Charting Kidney Cancer Metabolism
Changes in cell metabolism are increasingly recognized as an important way tumors develop and progress, yet these changes are hard to measure and interpret. A new tool designed by MSK scientists allows users to identify metabolic changes in kidney cancer tumors that may one day be targets for therapy.
Improving Regenerative Medicine
Lab-created stem cells may lack key characteristics, UCLA research finds.
Tick Genome Reveals Secrets of a Successful Bloodsucker
NIH has announced that decipher the genome of the blacklegged tick which could lead to new tick control methods.
"Dark Side" of the Transcriptome
New approach to quantifying gene "read-outs" reveals important variations in protein synthesis and has implications for understanding neurodegenerative diseases.
Individuals' Medical Histories Predicted by their Noncoding Genomes
Researchers have found that analyzing mutations in regions of the genome that control genes can predict medical conditions such as hypertension, narcolepsy and heart problems.
'Molecular Movie' Opens Door to New Cancer Treatments
An international team of scientists led by the University of Liverpool has produced a 'structural movie' revealing the step-by-step creation of an important naturally occurring chemical in the body that plays a role in some cancers.
New Source of Mutations in Cancer
Recently, a new mutation signature found in cancer cells was suspected to have been created by a family of enzymes found in human cells called the APOBEC3 family.
Advancing Synthetic Biology
Living systems rely on a dizzying variety of chemical reactions essential to development and survival. Most of these involve a specialized class of protein molecules — the enzymes.
Madison Researchers Begin Work on Zika Virus
Work will start with basic questions about Zika virus infection.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!